Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.52 |
| ▸ | ALDH5A1 | P51649 | 3/20 | 0.47 |
| ▸ | ABAT | P80404 | 3/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 2/20 | 0.42 |
| ▸ | ERN1 | O75460 | 2/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31260317 | 1.00 | KDM4E (0.64) | KDM4EPTGS2RAB9AALDH1A1AOX1 | |
| SCHEMBL151496 | 0.82 | KDM4E (0.64) | KDM4EPTGS2RAB9AALDH1A1AOX1 | |
| SCHEMBL6902242 | 0.78 | ALDH1A1 (0.46) | KDM4EPTGS2RAB9AALDH1A1AOX1 | |
| Protocatechualdehyde SCHEMBL36350 | 0.78 | KDM4E (1.00) | KDM4EPTGS2RAB9AALDH1A1AOX1 | |
| Protocatechualdehyde SCHEMBL29349539 | 0.78 | KDM4E (1.00) | KDM4EPTGS2RAB9AALDH1A1AOX1 | |
| Protocatechualdehyde SCHEMBL9512877 | 0.78 | KDM4E (1.00) | KDM4EPTGS2RAB9AALDH1A1AOX1 | |
| Protocatechualdehyde SCHEMBL28071658 | 0.77 | KDM4E (0.86) | KDM4EPTGS2RAB9AALDH1A1AOX1 | |
| Protocatechualdehyde SCHEMBL4072910 | 0.76 | KDM4E (0.95) | KDM4EPTGS2RAB9AALDH1A1AOX1 | |
| Protocatechualdehyde SCHEMBL27876787 | 0.76 | KDM4E (0.95) | KDM4EPTGS2RAB9AALDH1A1AOX1 | |
| Protocatechualdehyde SCHEMBL27748932 | 0.76 | KDM4E (0.95) | KDM4EPTGS2RAB9AALDH1A1AOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100500648-C | Synthesizing process of nitro iodo phenol cyanide | UNIV ZHEJIANG TECHNOLOGY (CN) | 2009-06-17 | — | — | CN | claimed |
| CN-100999484-A | Synthesizing process of nitro iodo phenol cyanide | UNIV ZHEJIANG TECHNOLOGY (CN) | 2007-07-18 | — | — | CN | claimed |
| EP-0488860-B1 | Method for the production of polyalkoxylated aromatic compounds | RHONE POULENC CHIMIE (FR) | 1995-10-11 | — | — | EP | claimed |
| EP-0423010-B1 | METHOD FOR THE PRODUCTION OF ALKOXYBENZALDEHYDES | RHONE-POULENC CHIMIE (FR) | 1993-09-29 | — | — | EP | claimed |
| EP-4716685-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-20260070906-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-3891149-B1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | GENZYME CORPORATION | 2025-12-23 | — | — | US | disclosed |
| US-12459941-B2 | Tricyclic IRAK inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-3820465-B1 | SOLAR CELL DYES FOR COPPER REDOX BASED DYE SENSITIZED SOLAR CELLS AND COMBINATIONS THEREOF | AMBIENT PHOTONICS INC (US) | 2025-09-17 | — | — | EP | disclosed |
| CN-120136703-A | Compound, polymer, composition for film formation, pattern formation method, method for forming insulating film, and method for producing compound | 三菱瓦斯化学株式会社 | 2025-06-13 | — | — | CN | disclosed |
| CN-120136704-A | Compound, polymer, composition for film formation, pattern formation method, method for forming insulating film, and method for producing compound | 三菱瓦斯化学株式会社 | 2025-06-13 | — | — | CN | disclosed |
| EP-1861392-A2 | SUBSTITUTED OXINDOL DERIVATIVES, DRUGS CONTAINING SAID DERIVATIVES AND THE USE THEREOF | Abbott GmbH & Co. KG (DE) | 2007-12-05 | — | — | EP | disclosed |
| CN-100999484-A | Synthesizing process of nitro iodo phenol cyanide | UNIV ZHEJIANG TECHNOLOGY (CN) | 2007-07-18 | — | — | CN | disclosed |
| WO-2007071638-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. ORGANON (NL) | 2007-06-28 | — | — | WO | disclosed |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2007-06-28 | — | — | US | disclosed |
| WO-2007063123-A1 | SUBSTITUTED OXINDOL-DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2007-06-07 | — | — | WO | disclosed |
| WO-2006100082-A2 | SUBSTITUTED OXINDOL DERIVATIVES, DRUGS CONTAINING SAID DERIVATIVES AND THE USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006100082-A2 | SUBSTITUTED OXINDOL DERIVATIVES, DRUGS CONTAINING SAID DERIVATIVES AND THE USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2006-09-28 | — | — | WO | disclosed |
| CN-1768050-A | Benzopyran compounds for the treatment of inflammation | PHARMACIA CORP (US) | 2006-05-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | NR3C1, NR3C2, MC2R | KDM4E 2478/4885PTGS2 2428/4885RAB9A 2582/4885 |
| US-12459941-B2 | Tricyclic IRAK inhibitors | IRAK1, IRAK2, IRAK3 | KDM4E 573/4885PTGS2 2737/4885RAB9A 3079/4885 |
| US-20260070906-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | TLR1, TLR6, TLR8 | KDM4E 1496/4885PTGS2 1342/4885RAB9A 1916/4885 |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | CSF1R, CSF3R, IL1RN | KDM4E 3985/4885PTGS2 1477/4885RAB9A 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.